# EDGAR Filing Document

**Accession Number:** 0001571123
**File Stem:** 0001571123-26-000025
**Filing Date:** 2026-3
**Character Count:** 53764
**Document Hash:** 738f842c63d7524e5cdde33c35878b0f
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0001571123-26-000025.hdr.sgml**: 20260316

**ACCESSION NUMBER**: 0001571123-26-000025

**CONFORMED SUBMISSION TYPE**: 8-K

**PUBLIC DOCUMENT COUNT**: 12

**CONFORMED PERIOD OF REPORT**: 20260316

**ITEM INFORMATION**: Results of Operations and Financial Condition

**ITEM INFORMATION**: Financial Statements and Exhibits

**FILED AS OF DATE**: 20260316

**DATE AS OF CHANGE**: 20260316

**FILER**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** Science Applications International Corp
- **CENTRAL INDEX KEY:** 0001571123
- **STANDARD INDUSTRIAL CLASSIFICATION:** SERVICES-COMPUTER INTEGRATED SYSTEMS DESIGN [7373]
- **ORGANIZATION NAME:** 06 Technology
- **EIN:** 461932921
- **STATE OF INCORPORATION:** DE
- **FISCAL YEAR END:** 0130

**FILING VALUES:**
- **FORM TYPE:** 8-K
- **SEC ACT:** 1934 Act
- **SEC FILE NUMBER:** 001-35832
- **FILM NUMBER:** 26754400

**BUSINESS ADDRESS:**
- **STREET 1:** 12010 SUNSET HILLS ROAD
- **CITY:** RESTON
- **STATE:** VA
- **ZIP:** 20190
- **BUSINESS PHONE:** 703-676-4300

**MAIL ADDRESS:**
- **STREET 1:** 12010 SUNSET HILLS ROAD
- **CITY:** RESTON
- **STATE:** VA
- **ZIP:** 20190

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** SAIC Gemini, Inc.
- **DATE OF NAME CHANGE:** 20130305

?xml version='1.0' encoding='ASCII'? saic-20260316

    

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

**Washington, D.C. 20549**

_________________________________________________________

Form 8-K

_________________________________________________________

**CURRENT REPORT**

**Pursuant to Section 13 or 15(d)**

**of the Securities Exchange Act of 1934**

**Date of Report (Date of earliest event reported): March 16, 2026** 

_________________________________________________________

Science Applications International Corporation

**(Exact name of registrant as specified in its charter)**

_________________________________________________________

---

| | | |
|:---|:---|:---|
| Delaware | 001-35832 | 46-1932921 |
| **(State or other Jurisdiction<br>of Incorporation)** | **(Commission<br>File Number)** | **(IRS Employer<br>Identification No.)** |

---

12010 Sunset Hills Road, Reston, VA 20190

**(Address of Principal Executive Offices) (Zip Code)**

(703) 676-4300

**Registrant's telephone number, including area code**

Not Applicable

**(Former name or former address if changed since last report.)** 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

---

| | | |
|:---|:---|:---|
| **<u>Title of each class</u>** | **<u>Trading Symbol(s)</u>** | **<u>Name of each exchange on which registered</u>** |
| **Common Stock, par value $.0001 per share** | **SAIC** | **The Nasdaq Stock Market LLC** |

---

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

    

------

**Item 2.02. *Results of Operations and Financial Condition***

On March 16, 2026, Science Applications International Corporation issued a press release announcing its financial results for the fourth fiscal quarter and full fiscal year ended January 30, 2026. A copy of the press release is furnished as Exhibit 99.1 to this report.

The Company's management will discuss operations and financial results in an earnings conference call beginning at 10:00 a.m. Eastern time on March 16, 2026. A live audio broadcast of the conference call along with a supplemental presentation will be available to the public through links on the Investor Relations section of the Company's website (http://investors.saic.com).

The information contained in this report, including Exhibit 99.1, shall not be deemed to be "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (Exchange Act), or otherwise subject to the liabilities of that section, and shall not be incorporated by reference into any registration statement or other document filed under the Securities Act of 1933, as amended, or the Exchange Act, except as shall be expressly set forth by specific reference in such filing.

**Item 9.01. *Financial Statements and Exhibits***

(d) Exhibits.

---

| | |
|:---|:---|
| **Exhibit<br>Number** | **Description of Exhibit** |
| <u>[99.1](saic031620268kexhibit991.htm)</u> | Press Release dated March 16, 2026 |
| 104 | The cover page from this Current Report on Form 8-K, formatted as Inline XBRL |

---

------

**SIGNATURES**

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

Date: March 16, 2026

Science Applications International Corporation

---

| | |
|:---|:---|
| By: | /s/ Hilary L. Hageman |
|  | **Hilary L. Hageman** |
|  | **Executive Vice President, General Counsel and Corporate Secretary** |

---

## Exhibit 99.1

**Exhibit 99.1**

**SAIC Announces Fourth Quarter and Full Fiscal Year 2026 Results**

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;***• Q4 FY26 revenues of $1.75 billion; FY26 revenues of $7.26 billion***

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;***• Q4 FY26 net income of $85 million, adjusted EBITDA***<sup>(1)</sup> ***of $181 million or 10.3% of revenue; FY26 net income of $358 million, adjusted EBITDA***<sup>(1)</sup> ***of $708 million or 9.7% of revenue***

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;***• Q4 FY26 diluted earnings per share of $1.87, adjusted diluted earnings per share***<sup>(1)</sup> ***of $2.62; FY26 diluted earnings per share of $7.70, adjusted diluted earnings per share***<sup>(1)</sup> ***of $10.75***

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;***• Q4 FY26 cash flows provided by operating activities of $258 million, free cash flow***<sup>(1)</sup> ***of $336 million; FY26 cash flows provided by operating activities of $609 million, free cash flow***<sup>(1)</sup> ***of $577 million***

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;***• Q4 FY26 net bookings of $0.6 billion; book-to-bill ratio of 0.3; trailing twelve months book-to-bill ratio of 1.1***

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;***• Announces FY27 guidance for adjusted diluted earnings per share***<sup>(1)</sup> ***and reiterates revenue, adjusted EBITDA***<sup>(1)</sup>***, adjusted EBITDA margin***<sup>(1)</sup>***, and free cash flow***<sup>(1)</sup> ***guidance***

RESTON, VA, March 16, 2026—Science Applications International Corporation (NASDAQ: SAIC), a premier Fortune 500 technology integrator driving our nation's digital transformation across the defense, space, civilian, and intelligence markets, today announced results for the fourth quarter and full fiscal year ended January 30, 2026.

"As previously announced on February 11, our fourth-quarter results reflected ongoing top-line challenges, balanced by strong operational execution that supports our ability to raise margin expectations moving forward," said Jim Reagan, SAIC's Chief Executive Officer. "I am encouraged by the progress we are making and by the opportunities in front of us. Our plan is simple – we will focus on elements within our control to drive more consistent and reliable growth. With a career dedicated to operational excellence and value creation in our industry, I am honored to continue, as permanent CEO, building on SAIC's solid foundation to deliver meaningful results to all stakeholders."

**<u>Fourth Quarter and Full Fiscal Year 2026: Summary Operating Results</u>**

---

| | | | | | | |
|:---|:---|:---|:---|:---|:---|:---|
| | **Three Months Ended** | **Three Months Ended** | **Three Months Ended** | **Year Ended** | **Year Ended** | **Year Ended** |
|  | **January 30, 2026** | *Percent<br>change* | January 31, 2025 | **January 30, 2026** | *Percent<br>change* | January 31, 2025 |
|  | (dollars in millions, except per share amounts) | (dollars in millions, except per share amounts) | (dollars in millions, except per share amounts) | (dollars in millions, except per share amounts) | (dollars in millions, except per share amounts) | (dollars in millions, except per share amounts) |
| Revenues | $**1750** | *(5) %* | $1838 | $**7262** | *(3) %* | $7479 |
| Operating income | **133** | *(4) %* | 138 | **521** | *(7) %* | 563 |
| &nbsp;&nbsp;&nbsp;*Operating income as a percentage of revenues* | ***7.6*** *%*** | *10bps* | *7.5 %* | ***7.2*** *%*** | *-30bps* | *7.5 %* |
| Adjusted operating income<sup>(1)</sup> | **179** | *2 %* | 176 | **702** | *— %* | 705 |
| &nbsp;&nbsp;&nbsp;*Adjusted operating income as a percentage of revenues* | ***10.2*** *%*** | *60bps* | *9.6 %* | ***9.7*** *%*** | *30bps* | *9.4 %* |
| Net income | **85** | *(13) %* | 98 | **358** | *(1) %* | 362 |
| EBITDA<sup>(1)</sup> | **175** | *— %* | 175 | **676** | *(5) %* | 708 |
| &nbsp;&nbsp;&nbsp;*EBITDA as a percentage of revenues* | ***10.0*** *%*** | *50bps* | *9.5 %* | ***9.3*** *%*** | *-20bps* | *9.5 %* |
| Adjusted EBITDA<sup>(1)</sup> | **181** | *2 %* | 177 | **708** | *— %* | 710 |
| &nbsp;&nbsp;&nbsp;*Adjusted EBITDA as a percentage of revenues* | ***10.3*** *%*** | *70bps* | *9.6 %* | ***9.7*** *%*** | *20bps* | *9.5 %* |
| Diluted earnings per share | $**1.87** | *(7) %* | $2.00 | $**7.70** | *7 %* | $7.17 |
| Adjusted diluted earnings per share<sup>(1)</sup> | $**2.62** | *2 %* | $2.57 | $**10.75** | *18 %* | $9.13 |
| Net cash provided by operating activities | $**258** | *124 %* | $115 | $**609** | *23 %* | $494 |
| Free cash flow<sup>(1)</sup> | $**336** | *42 %* | $236 | $**577** | *16 %* | $499 |

---

<sup>(1)</sup> *Non-GAAP measure, see Schedule 6 for information about this measure.*

------

**<u>Fourth Quarter Summary Results</u>**

Revenues for the quarter decreased $88 million compared to the prior year quarter primarily due to ramp down in volume on existing contracts, including the impact of government shutdown, and contract completions, partially offset by new contracts and the acquisition of SilverEdge ($23 million).

Operating income as a percentage of revenues increased to 7.6% for the quarter as compared to 7.5% in the comparable prior year period primarily due to lower selling, general and administrative expenses, partially offset by timing and volume mix in our contract portfolio.

Adjusted EBITDA<sup>(1)</sup> as a percentage of revenues for the quarter was 10.3%, compared to 9.6% for the prior year quarter primarily due to lower selling, general and administrative expenses, partially offset by timing and volume mix in our contract portfolio.

Diluted earnings per share for the quarter was $1.87 compared to $2.00 in the prior year quarter. Adjusted diluted earnings per share<sup>(1)</sup> was $2.62 for the quarter compared to $2.57 in the prior year quarter. The weighted-average diluted shares outstanding during the quarter decreased to 45.4 million shares from 49.0 million shares during the prior year quarter.

<sup>(1)</sup> *Non-GAAP measure, see Schedule 6 for information about this measure.*

**<u>Fiscal Year 2026 Summary Results</u>**

Revenues for the fiscal year decreased $217 million compared to the prior year primarily due to contract completions and ramp down in volume on existing contracts, including approximately $26 million attributable to the government shutdown, partially offset by new contracts. Revenues attributed to SilverEdge for the year ended January 30, 2026 were $27 million. Adjusting for the acquisition of SilverEdge, revenues contracted by approximately 3.3%.

Operating income as a percentage of revenues for the fiscal year decreased compared to the prior year primarily due to executive transition costs, net of recoveries, the favorable resolution of the Assault Amphibious Vehicle ("AAV") contract termination in the prior year ($13 million), costs related to the settlement of federal tax audits, and timing and volume mix in our contract portfolio, partially offset by a recovery of costs from the settlement of a patent infringement matter.

Adjusted EBITDA<sup>(1)</sup> as a percentage of revenues for the fiscal year increased compared to the prior year primarily due to a recovery of costs from the settlement of a patent infringement matter and lower other selling, general and administrative expenses, partially offset by the favorable resolution of the AAV contract termination in the prior year ($13 million), and timing and volume mix in our contract portfolio.

Diluted earnings per share for the year was $7.70 compared to $7.17 in the prior year. Adjusted diluted earnings per share<sup>(1)</sup> was $10.75 for the year compared to $9.13 in the prior year. The weighted-average diluted shares outstanding during the year decreased to 46.5 million shares from 50.5 million shares during the prior year.

<sup>(1)</sup> *Non-GAAP measure, see Schedule 6 for information about this measure.*

**<u>Cash Generation and Capital Deployment</u>**

Total cash flows provided by operating activities for the fourth quarter were $258 million, an increase of $143 million compared to the prior year quarter, primarily due to timing of customer collections, lower cash outflows from the usage of the Master Accounts Receivable Purchase Agreement ("MARPA Facility"), and lower cash taxes paid, net of tax refunds received in the current year, partially offset by timing of vendor payments.

Total cash flows provided by operating activities for the year were $609 million, an increase of $115 million from the prior year, primarily due to timing of customer collections, lower cash outflows from the usage of the MARPA Facility, lower cash taxes paid, net of tax refunds received in the current year, and other changes in working capital, partially offset by timing of vendor payments.

During the quarter, SAIC deployed $122 million of capital, consisting primarily of $97 million of share repurchases in accordance with established repurchase plans and $17 million in cash dividends to shareholders. For the year, SAIC deployed $524 million of capital, consisting primarily of share repurchases of $422 million (approximately 4.0 million shares) in accordance with established repurchase plans and cash dividends of $70 million to shareholders.

------

**<u>Quarterly Dividend Declared</u>**

As previously announced, subsequent to fiscal year-end, the Company's Board of Directors ("Board of Directors") declared a cash dividend of $0.37 per share of the Company's common stock payable on April 24, 2026 to stockholders of record on April 10, 2026. SAIC intends to continue paying dividends on a quarterly basis, although the declaration of any future dividends will be determined by the Board of Directors each quarter and will depend on earnings, financial condition, capital requirements and other factors.

**<u>Backlog and Contract Awards</u>** 

Net bookings for the quarter were approximately $0.6 billion, which reflects a book-to-bill ratio of approximately 0.3. Net bookings for the year were approximately $7.8 billion, which reflects a book-to-bill ratio of approximately 1.1.

SAIC's estimated backlog at the end of fiscal 2026 was approximately $22.6 billion of which $3.6 billion was funded.

SAIC was awarded the following notable contracts during the quarter:

*Notable Space and Intelligence Community Awards:*

**U.S. Space and Intelligence Community:** During the quarter, SAIC was awarded approximately $629 million of contract awards by space and intelligence organizations. These awards represent a combination of new business, modifications, and recompetes.

*Notable New Awards:*

**U.S. Government Accountability Office ("GAO"):** SAIC was awarded a new $95 million contract by the GAO to provide comprehensive, full-scale IT solutions for the Technical Information Services (TIS) program. Under this five-year (one-year base, plus four, one-year option periods) contract, the Company will deliver end-to-end IT solutions designed to support the GAO mission of a revamped and more efficient IT environment.

*Notable Awards Subsequent to Period End (not included in current quarter bookings):*

**U.S. Space and Intelligence Community:** Subsequent to the end of the quarter, SAIC was awarded a seven-year recompete contract of approximately $330 million with a Space and Intelligence Community customer. Under this contract, SAIC will provide systems engineering and technical assistance to its customer.

**Federal Civilian Community:** Subsequent to the end of the quarter, SAIC was awarded a five-year (one-year base, plus four, one-year option periods) recompete contract of approximately $200 million with an agency in its Civilian business group. Under this contract, SAIC will provide technology enhancement, modernization, and refresh of customer systems.

**<u>Fiscal Year 2027 Guidance</u>**

The Company's outlook for fiscal year 2027 is being provided, announcing guidance for adjusted diluted EPS<sup>(1)</sup> and reiterating the previously announced guidance for revenue, adjusted EBITDA<sup>(1)</sup>, adjusted EBITDA margin<sup>(1)</sup>, and free cash flow<sup>(1)</sup>. The table below summarizes fiscal year 2027 guidance and represents our views as of March 16, 2026.&nbsp;&nbsp;&nbsp;&nbsp;

---

| | |
|:---|:---|
| | **CURRENT Fiscal Year**<br>**2027 Guidance** |
| Revenue | $7.0B - $7.2B |
| Organic Growth | (4%) - (2%) |
| Adjusted EBITDA<sup>(1)</sup> | $705M - $715M |
| Adjusted EBITDA Margin %<sup>(1)</sup> | 9.9% - 10.1% |
| Adjusted Diluted EPS<sup>(1)</sup> | $9.50 - $9.70 |
| Free Cash Flow<sup>(1)</sup> | >$600M |

---

<sup>(1)</sup> *Non-GAAP measure, see Schedule 6 for information about this measure.*

**<u>Webcast Information</u>**

SAIC management will discuss operations and financial results in an earnings conference call beginning at 10 a.m. Eastern time on March 16, 2026. The conference call will be webcast simultaneously to the public through a link on the Investor Relations section of the SAIC website (http://investors.saic.com). We will be providing webcast access only – "dial-in"

------

access is no longer available. Additionally, a supplemental presentation will be available to the public through links to the Investor Relations section of the SAIC website. After the call concludes, an on-demand audio replay of the webcast can be accessed on the Investor Relations website.

**<u>About SAIC</u>**

SAIC<sup>®</sup> is a premier Fortune 500 mission integrator focused on advancing the power of technology and innovation to serve and protect our world. Our robust portfolio of offerings across the defense, space, civilian and intelligence markets includes secure high-end solutions in mission IT, enterprise IT, engineering services and professional services. We integrate emerging technology, rapidly and securely, into mission critical operations that modernize and enable critical national imperatives.

We are approximately 23,000 strong; driven by mission, united by purpose, and inspired by opportunities. Headquartered in Reston, Virginia, SAIC has annual revenues of approximately $7.3 billion. For more information, visit saic.com. For ongoing news, please visit our newsroom.

**<u>Media Contact</u>**

Darryn James

Director, Media and Brand Reputation

publicrelations@saic.com

**<u>Investor Relations Contact</u>**

Jon Raviv

Vice President, Investor Relations

investorrelations@saic.com

***<u>GAAP to Non-GAAP Guidance Reconciliation</u>***

*The Company does not provide a reconciliation of forward-looking adjusted diluted EPS to GAAP diluted EPS or adjusted EBITDA margin to GAAP net income due to the inherent difficulty in forecasting and quantifying certain amounts that are necessary for such reconciliation. Because certain deductions for non-GAAP exclusions used to calculate net income may vary significantly based on actual events, the Company is not able to forecast GAAP diluted EPS or GAAP net income with reasonable certainty. The variability of the above charges may have an unpredictable and potentially significant impact on our future GAAP financial results.*

***<u>Forward-Looking Statements</u>***

*Certain statements in this release contain or are based on "forward-looking" information within the meaning of the Private Securities Litigation Reform Act of 1995. In some cases, you can identify forward-looking statements by words such as "expects," "intends," "plans," "anticipates," "believes," "estimates," "guidance," and similar words or phrases. Forward-looking statements in this release may include, among others, estimates of future revenues, operating income, earnings, earnings per share, charges, total contract value, backlog, outstanding shares and cash flows, as well as statements about future dividends, share repurchases and other capital deployment plans. Such statements are not guarantees of future performance and involve risk, uncertainties and assumptions, and actual results may differ materially from the guidance and other forward-looking statements made in this release as a result of various factors. Risks, uncertainties and assumptions that could cause or contribute to these material differences include those discussed in the "Risk Factors," "Management's Discussion and Analysis of Financial Condition and Results of Operations" and "Legal Proceedings" sections of our Annual Report on Form 10-K, as updated in any subsequent Quarterly Reports on Form 10-Q and other filings with the SEC, which may be viewed or obtained through the Investor Relations section of our website at <u>www.saic.com</u> or on the SEC's website at www.sec.gov. Due to such risks, uncertainties and assumptions you are cautioned not to place undue reliance on such forward-looking statements, which speak only as of the date hereof. SAIC expressly disclaims any duty to update any forward-looking statement provided in this release to reflect subsequent events, actual results or changes in SAIC's expectations. SAIC also disclaims any duty to comment upon or correct information that may be contained in reports published by investment analysts or others.*

------

**Schedule 1:**

**SCIENCE APPLICATIONS INTERNATIONAL CORPORATION**

**CONDENSED AND CONSOLIDATED STATEMENTS OF INCOME**

**(Unaudited)**

---

| | | | | |
|:---|:---|:---|:---|:---|
| | **Three Months Ended** | **Three Months Ended** | **Year Ended** | **Year Ended** |
| | **January 30, 2026** | January 31, 2025 | **January 30, 2026** | January 31, 2025 |
| | (in millions, except per share amounts) | (in millions, except per share amounts) | (in millions, except per share amounts) | (in millions, except per share amounts) |
| Revenues | $**1750** | $1838 | $**7262** | $7479 |
| Cost of revenues | **1529** | 1606 | **6390** | 6587 |
| Selling, general and administrative expenses | **85** | 94 | **350** | 339 |
| Other operating (income) expense | **3** |  | **1** | (10) |
| Operating income | **133** | 138 | **521** | 563 |
| Interest expense, net | **34** | 29 | **128** | 126 |
| Other (income) expense, net | **—** | 2 | **6** | 9 |
| Income before income taxes | **99** | 107 | **387** | 428 |
| Provision for income taxes | **(14)** | (9) | **(29)** | (66) |
| Net income | $**85** | $98 | $**358** | $362 |
| Weighted-average number of shares outstanding: |  |  |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;Basic | **45.0** | 48.6 | **46.3** | 50.1 |
| &nbsp;&nbsp;&nbsp;&nbsp;Diluted | **45.4** | 49.0 | **46.5** | 50.5 |
| Earnings per share: |  |  |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;Basic | $**1.89** | $2.02 | $**7.73** | $7.23 |
| &nbsp;&nbsp;&nbsp;&nbsp;Diluted | $**1.87** | $2.00 | $**7.70** | $7.17 |

---

------

**Schedule 2:**

**SCIENCE APPLICATIONS INTERNATIONAL CORPORATION**

**CONDENSED AND CONSOLIDATED BALANCE SHEETS**

**(Unaudited)**

---

| | | |
|:---|:---|:---|
| | **January 30, 2026** | January 31, 2025 |
| | (in millions) | (in millions) |
| **ASSETS** |  |  |
| Current assets: |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;Cash and cash equivalents | $**182** | $56 |
| &nbsp;&nbsp;&nbsp;&nbsp;Receivables, net | **853** | 1000 |
| &nbsp;&nbsp;&nbsp;&nbsp;Prepaid expenses | **122** | 78 |
| &nbsp;&nbsp;&nbsp;&nbsp;Other current assets | **22** | 20 |
| Total current assets | **1179** | 1154 |
| Goodwill | **2944** | 2851 |
| Intangible assets, net | **761** | 779 |
| Property, plant, and equipment, net | **110** | 104 |
| Operating lease right of use assets | **193** | 164 |
| Other assets | **167** | 194 |
| Total assets | $**5354** | $5246 |
| **LIABILITIES AND EQUITY** |  |  |
| Current liabilities: |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;Accounts payable | $**500** | $631 |
| &nbsp;&nbsp;&nbsp;&nbsp;Accrued payroll and other employee benefits | **201** | 219 |
| &nbsp;&nbsp;&nbsp;&nbsp;Accrued vacation | **115** | 120 |
| &nbsp;&nbsp;&nbsp;&nbsp;Other accrued liabilities | **147** | 113 |
| &nbsp;&nbsp;&nbsp;&nbsp;Debt, current portion | **19** | 313 |
| Total current liabilities | **982** | 1396 |
| Debt, net of current portion | **2468** | 1907 |
| Operating lease liabilities | **198** | 173 |
| Deferred income taxes | **104** | 24 |
| Other long-term liabilities | **102** | 169 |
| Equity: |  |  |
| &nbsp;&nbsp;Total stockholders' equity | **1500** | 1577 |
| Total liabilities and stockholders' equity | $**5354** | $5246 |

---

------

**Schedule 3:**

**SCIENCE APPLICATIONS INTERNATIONAL CORPORATION**

**CONDENSED AND CONSOLIDATED STATEMENTS OF CASH FLOWS**

**(Unaudited)**

---

| | | | | |
|:---|:---|:---|:---|:---|
| | **Three Months Ended** | **Three Months Ended** | **Year Ended** | **Year Ended** |
| | **January 30, 2026** | January 31, 2025 | **January 30, 2026** | January 31, 2025 |
| | (in millions) | (in millions) | (in millions) | (in millions) |
| Cash flows from operating activities: |  |  |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;Net income | $**85** | $98 | $**358** | $362 |
| &nbsp;&nbsp;&nbsp;&nbsp;Adjustments to reconcile net income to net cash provided by operating activities: |  |  |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Depreciation and amortization | **40** | 36 | **149** | 140 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Deferred income taxes | **(20)** | 12 | **81** | (3) |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Stock-based compensation expense | **13** | 15 | **64** | 53 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Other | **5** | 2 | **1** | (7) |
| &nbsp;&nbsp;&nbsp;&nbsp;Increase (decrease) resulting from changes in operating assets and liabilities, net of the effect of the acquisitions and divestitures: |  |  |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Receivables | **192** | 22 | **161** | (86) |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Prepaid expenses and other current assets | **24** | (7) | **(44)** | 24 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Accounts payable and other accrued liabilities | **(79)** | (71) | **(101)** | 48 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Accrued payroll and employee benefits | **8** | 28 | **(28)** | (31) |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Operating lease assets and liabilities, net | **3** | 1 | **(2)** | (6) |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Other assets and other long-term liabilities, net | **(13)** | (21) | **(30)** |  |
| Net cash provided by operating activities | **258** | 115 | **609** | 494 |
| Cash flows from investing activities: |  |  |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;Cash paid for acquisition, net of cash acquired | **—** |  | **(203)** |  |
| &nbsp;&nbsp;&nbsp;&nbsp;Expenditures for property, plant, and equipment | **(8)** | (15) | **(32)** | (36) |
| &nbsp;&nbsp;&nbsp;&nbsp;Contributions to investments | **(1)** | (4) | **(11)** | (7) |
| &nbsp;&nbsp;&nbsp;&nbsp;Purchases of marketable securities | **(4)** | (3) | **(9)** | (14) |
| &nbsp;&nbsp;&nbsp;&nbsp;Sales of marketable securities | **2** | 2 | **7** | 12 |
| &nbsp;&nbsp;&nbsp;&nbsp;Proceeds from sale of equity method investments | **—** |  | **—** | 10 |
| Net cash used in investing activities | **(11)** | (20) | **(248)** | (35) |
| Cash flows from financing activities: |  |  |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;Proceeds from borrowings | **—** | 385 | **2745** | 1499 |
| &nbsp;&nbsp;&nbsp;&nbsp;Principal payments on borrowings | **(1)** | (325) | **(2474)** | (1381) |
| &nbsp;&nbsp;&nbsp;&nbsp;Stock repurchased and retired or withheld for taxes on equity awards | **(98)** | (133) | **(445)** | (558) |
| &nbsp;&nbsp;&nbsp;&nbsp;Dividend payments to stockholders | **(17)** | (18) | **(70)** | (75) |
| &nbsp;&nbsp;&nbsp;&nbsp;Issuances of stock | **6** | 6 | **22** | 20 |
| &nbsp;&nbsp;&nbsp;&nbsp;Debt issuance costs | **—** |  | **(9)** |  |
| &nbsp;&nbsp;&nbsp;&nbsp;Other | **—** |  | **(4)** | (3) |
| Net cash used in financing activities | **(110)** | (85) | **(235)** | (498) |
| Net increase (decrease) in cash, cash equivalents and restricted cash | **137** | 10 | **126** | (39) |
| Cash, cash equivalents and restricted cash at beginning of period | **53** | 54 | **64** | 103 |
| Cash, cash equivalents and restricted cash at end of period | $**190** | $64 | $**190** | $64 |

---

------

**Schedule 4:**

**SCIENCE APPLICATIONS INTERNATIONAL CORPORATION**

**SEGMENT OPERATING RESULTS**

**(Unaudited)**

---

| | | | | |
|:---|:---|:---|:---|:---|
| | **Three Months Ended** | **Three Months Ended** | **Year Ended** | **Year Ended** |
| | **January 30,<br>2026** | January 31,<br>2025 | **January 30,<br>2026** | January 31,<br>2025 |
| | (dollars in millions) | (dollars in millions) | (dollars in millions) | (dollars in millions) |
| **Revenues** |  |  |  |  |
| &nbsp;&nbsp;&nbsp;Defense and Intelligence | $**1335** | $1360 | $**5581** | $5726 |
| &nbsp;&nbsp;&nbsp;Civilian | **415** | 478 | **1681** | 1753 |
| Total revenues | $**1750** | $1838 | $**7262** | $7479 |
| **Adjusted operating income (loss)** |  |  |  |  |
| &nbsp;&nbsp;Defense and Intelligence | $**121** | $113 | $**478** | $509 |
| &nbsp;&nbsp;Civilian | **60** | 75 | **228** | 216 |
| &nbsp;&nbsp;Corporate | **(2)** | (12) | **(4)** | (20) |
| Total adjusted operating income | $**179** | $176 | $**702** | $705 |
| **Adjusted operating margin** |  |  |  |  |
| &nbsp;&nbsp;Defense and Intelligence | **9.1%** | 8.3% | **8.6%** | 8.9% |
| &nbsp;&nbsp;Civilian | **14.5%** | 15.7% | **13.6%** | 12.3% |
| Total adjusted operating margin | **10.2%** | 9.6% | **9.7%** | 9.4% |

---

**<u>Defense and Intelligence Results</u>**

Revenues in the fourth quarter decreased $25 million or 2% compared to the same period in the prior year primarily due to ramp down in volume on existing contracts and contract completions, partially offset by new contracts and the acquisition of SilverEdge ($23 million).

Revenues in the fiscal year decreased $145 million or 3% compared to the prior year primarily due to contract completions and ramp down in volume on existing contracts, partially offset by new contracts. Revenues attributed to SilverEdge for the year ended January 30, 2026 were $27 million.

Adjusted operating income as a percentage of revenues in the fourth quarter increased compared to the same period in the prior year primarily due to timing and volume mix in the contract portfolio.

Adjusted operating income as a percentage of revenues in the fiscal year decreased from the prior year primarily due to contract completions and ramp down in volume on existing contracts and the favorable resolution of the AAV contract termination in the prior year ($13 million), partially offset by new contracts.

**<u>Civilian Results</u>**

Revenues in the fourth quarter decreased $63 million or 13% compared to the same period in the prior year primarily due to ramp down in volume on existing contracts and contract completions, partially offset by new contracts.

Revenues in the fiscal year decreased $72 million or 4% compared to the prior year primarily due to ramp down in volume on existing contracts and contract completions, partially offset by new contracts.

Adjusted operating income as a percentage of revenues in the fourth quarter decreased compared to the same period in the prior year primarily due to timing and volume mix in the contract portfolio.

------

Adjusted operating income as a percentage of revenues in the fiscal year increased compared to the prior year primarily due to improved profitability across the contract portfolio.

**<u>Corporate Results</u>**

Adjusted operating loss in the fourth quarter decreased $10 million compared to the same period in the prior year primarily due to lower selling, general and administrative expenses.

Adjusted operating loss in the fiscal year decreased $16 million compared to the prior year primarily due to recovery of costs from the settlement of a patent infringement matter and lower other selling, general and administrative expenses.

------

**Schedule 5:**

**SCIENCE APPLICATIONS INTERNATIONAL CORPORATION**

**BACKLOG**

**(Unaudited)**

The estimated value of our total backlog as of the dates presented was:

---

| | | | | | | |
|:---|:---|:---|:---|:---|:---|:---|
| | **January 30, 2026** | **January 30, 2026** | **January 30, 2026** | January 31, 2025 | January 31, 2025 | January 31, 2025 |
| | Defense and Intelligence | Civilian | Total SAIC | Defense and Intelligence | Civilian | Total SAIC |
| | (in millions) | (in millions) | (in millions) | (in millions) | (in millions) | (in millions) |
| Funded backlog | $**2511** | $**1061** | $**3572** | $2599 | $845 | $3444 |
| Negotiated unfunded backlog | **15869** | **3181** | **19050** | 15341 | 3072 | 18413 |
| **Total backlog** | $**18380** | $**4242** | $**22622** | $17940 | $3917 | $21857 |

---

*Backlog represents the estimated amount of future revenues to be recognized under negotiated contracts and task orders as work is performed and excludes contract awards which have been protested by competitors until the protest is resolved in our favor. SAIC segregates backlog into two categories, funded backlog and negotiated unfunded backlog. Funded backlog for contracts with government agencies primarily represents contracts for which funding is appropriated less revenues previously recognized on these contracts, and does not include the unfunded portion of contracts where funding is incrementally appropriated or authorized by the U.S. government and other customers even though the contract may call for performance over a number of years. Funded backlog for contracts with non-government agencies represents the estimated value of contracts which may cover multiple future years under which SAIC is obligated to perform, less revenues previously recognized on these contracts. Negotiated unfunded backlog represents the estimated future revenues to be earned from negotiated contracts for which funding has not been appropriated or authorized, and unexercised priced contract options. Negotiated unfunded backlog does not include any estimate of future potential task orders expected to be awarded under indefinite delivery, indefinite quantity (IDIQ), U.S. General Services Administration (GSA) schedules or other master agreement contract vehicles, with the exception of certain IDIQ contracts where task orders are not competitively awarded and separately priced but instead are used as a funding mechanism, and where there is a basis for estimating future revenues and funding on future anticipated task orders.*

------

**Schedule 6:**

**SCIENCE APPLICATIONS INTERNATIONAL CORPORATION**

**NON-GAAP FINANCIAL MEASURES** 

**(Unaudited)**

This schedule describes the consolidated non-GAAP financial measures included in this earnings release. While we believe that these non-GAAP financial measures may be useful in evaluating our financial information, they should be considered as supplemental in nature and not as a substitute for financial information prepared in accordance with GAAP. Reconciliations, definitions, and how we believe these measures are useful to management and investors are provided below. Other companies may define similar measures differently.

**<u>Adjusted Operating Income</u>**

---

| | | | | |
|:---|:---|:---|:---|:---|
| | **Three Months Ended** | **Three Months Ended** | **Year Ended** | **Year Ended** |
| | **January 30, 2026** | January 31, 2025 | **January 30, 2026** | January 31, 2025 |
| | (dollars in millions) | (dollars in millions) | (dollars in millions) | (dollars in millions) |
| **Revenues** | $**1750** | $1838 | $**7262** | $7479 |
| **Operating income** | $**133** | $138 | $**521** | $563 |
| &nbsp;&nbsp;*Operating income as a percentage of revenues* | ***7.6*** *%*** | *7.5 %* | ***7.2*** *%*** | *7.5 %* |
| Depreciation of property, plant, and equipment | **8** | 8 | **30** | 25 |
| Amortization of intangible assets | **32** | 28 | **119** | 115 |
| Acquisition, integration, restructuring and impairment costs | **11** | 4 | **16** | 6 |
| Depreciation included in restructuring and impairment costs | **(1)** | (1) | **(1)** | (1) |
| Recovery of acquisition, integration, restructuring and impairment costs | **(4)** | (1) | **(6)** | (3) |
| Executive transition costs, net of recoveries | **—** |  | **16** |  |
| Costs related to the settlement of federal tax audits | **—** |  | **7** |  |
| **Adjusted operating income**<sup>(1)</sup> | $**179** | $176 | $**702** | $705 |
| &nbsp;&nbsp;*Adjusted operating income as a percentage of revenues* | ***10.2*** *%*** | *9.6 %* | ***9.7*** *%*** | *9.4 %* |

---

*Adjusted operating income is a performance measure that primarily excludes the impact of non-recurring transactions and activities that we do not consider to be indicative of our ongoing operating performance. Adjusted operating income is calculated by taking operating income and excluding depreciation and amortization, acquisition, integration, restructuring, and impairment costs, and any other material non-recurring costs. Acquisition, integration, restructuring and impairment costs represent costs incurred related to acquisitions, reorganizations, facilities optimization efforts, and impairments of long-lived assets, along with associated depreciation. Recovery of acquisition, integration, restructuring and impairment costs represents costs recovered through our indirect rates in accordance with Cost Accounting Standards. Depreciation of property, plant, and equipment relates to property, plant, and equipment specifically identifiable for each segment and Corporate. Adjusted operating income also excludes amortization of intangible assets because we do not have a history of significant acquisition activity, and therefore consider acquisitions to be a non-recurring activity, and the amount of an acquisition's purchase price allocated to intangible assets and the related amortization term are unique to each acquisition. Executive transition costs, net of recoveries, represent costs associated with the departure of our CEO and other executives in the third quarter of the fiscal year 2026, net of the portion recovered through our indirect rates in accordance with Cost Accounting Standards. Costs related to the settlement of federal tax audits represent costs related to the IRS audit settlement for fiscal years 2016 through 2019. We believe that adjusted operating income provides management and investors with useful information in assessing trends in our ongoing operating performance and may provide greater visibility in understanding our long-term financial performance.*

<sup>(1)</sup> *Non-GAAP measure, see above for definition.*

------

**Schedule 6 (continued):**

**SCIENCE APPLICATIONS INTERNATIONAL CORPORATION**

**NON-GAAP FINANCIAL MEASURES** 

**(Unaudited)**

**<u>EBITDA and Adjusted EBITDA</u>**

---

| | | | | |
|:---|:---|:---|:---|:---|
| | **Three Months Ended** | **Three Months Ended** | **Year Ended** | **Year Ended** |
| | **January 30, 2026** | January 31, 2025 | **January 30, 2026** | January 31, 2025 |
| | (dollars in millions) | (dollars in millions) | (dollars in millions) | (dollars in millions) |
| **Revenues** | $**1750** | $1838 | $**7262** | $7479 |
| **Net income** | $**85** | $98 | $**358** | $362 |
| Interest expense, net and loss on sale of receivables | **36** | 32 | **140** | 140 |
| Provision for income taxes | **14** | 9 | **29** | 66 |
| Depreciation and amortization | **40** | 36 | **149** | 140 |
| **EBITDA**<sup>(1)</sup> | **175** | 175 | **676** | 708 |
| &nbsp;&nbsp;&nbsp;*EBITDA as a percentage of revenues* | ***10.0*** *%*** | *9.5 %* | ***9.3*** *%*** | *9.5 %* |
| Acquisition, integration, restructuring and impairment costs | **11** | 4 | **16** | 6 |
| Depreciation included in restructuring and impairment costs | **(1)** | (1) | **(1)** | (1) |
| Recovery of acquisition, integration, restructuring and impairment costs | **(4)** | (1) | **(6)** | (3) |
| Executive transition costs, net of recoveries | **—** |  | **16** |  |
| Costs related to the settlement of federal tax audits | **—** |  | **7** |  |
| **Adjusted EBITDA**<sup>(1)</sup> | $**181** | $177 | $**708** | $710 |
| &nbsp;&nbsp;&nbsp;*Adjusted EBITDA as a percentage of revenues* | ***10.3*** *%*** | *9.6 %* | ***9.7*** *%*** | *9.5 %* |

---

*The performance measure EBITDA is calculated by taking net income and excluding interest and loss on sale of receivables, provision for income taxes, and depreciation and amortization. Adjusted EBITDA is a performance measure that excludes the impact of non-recurring transactions and activities that we do not consider to be indicative of our ongoing operating performance. Adjusted EBITDA is calculated by taking EBITDA and excluding acquisition, integration, restructuring and impairment costs, and any other material non-recurring costs. Acquisition, integration, restructuring and impairment costs represent costs incurred related to acquisitions, reorganizations, facilities optimization efforts, and impairments of long-lived assets, along with associated depreciation. Recovery of acquisition, integration, restructuring and impairment costs represents costs recovered through our indirect rates in accordance with Cost Accounting Standards. Executive transition costs, net of recoveries, represent costs associated with the departure of our CEO and other executives in the third quarter of the fiscal year 2026, net of the portion recovered through our indirect rates in accordance with Cost Accounting Standards. Costs related to the settlement of federal tax audits represent costs related to the IRS audit settlement for fiscal years 2016 through 2019. We believe that EBITDA and adjusted EBITDA provide management and investors with useful information in assessing trends in our ongoing operating performance and may provide greater visibility in understanding the long-term financial performance of our Company.*

<sup>(1)</sup> *Non-GAAP measure, see above for definition.*

------

**Schedule 6 (continued):**

**SCIENCE APPLICATIONS INTERNATIONAL CORPORATION**

**NON-GAAP FINANCIAL MEASURES**

**(Unaudited)**

**<u>Adjusted Diluted Earnings Per Share</u>**

---

| | | | | | |
|:---|:---|:---|:---|:---|:---|
| | **Three Months Ended January 30, 2026** | **Three Months Ended January 30, 2026** | **Three Months Ended January 30, 2026** | **Three Months Ended January 30, 2026** | **Three Months Ended January 30, 2026** |
| | **As Reported** | Amortization of intangible assets | Acquisition, integration, restructuring and impairment costs | Recovery of acquisition, integration, restructuring and impairment costs | **Non-GAAP results**<sup>(1)</sup> |
| | (in millions, except per share amounts) | (in millions, except per share amounts) | (in millions, except per share amounts) | (in millions, except per share amounts) | (in millions, except per share amounts) |
| Income before income taxes | $**99** | $32 | $11 | $(4) | $**138** |
| Income tax expense | **(14)** | (5) | (1) | 1 | **(19)** |
| Net income | $**85** | $27 | $10 | $(3) | $**119** |
| Diluted EPS | $**1.87** | $0.60 | $0.22 | $(0.07) | $**2.62** |

---

---

| | | | | | |
|:---|:---|:---|:---|:---|:---|
| | **Three Months Ended January 31, 2025** | **Three Months Ended January 31, 2025** | **Three Months Ended January 31, 2025** | **Three Months Ended January 31, 2025** | **Three Months Ended January 31, 2025** |
| | **As Reported** | Amortization of intangible assets | Acquisition, integration, restructuring and impairment costs | Recovery of acquisition, integration, restructuring and impairment costs | **Non-GAAP results**<sup>(1)</sup> |
| | (in millions, except per share amounts) | (in millions, except per share amounts) | (in millions, except per share amounts) | (in millions, except per share amounts) | (in millions, except per share amounts) |
| Income before income taxes | $**107** | $28 | $4 | $(1) | $**138** |
| Income tax expense | **(9)** | (2) | (1) |  | **(12)** |
| Net Income | $**98** | $26 | $3 | $(1) | $**126** |
| Diluted EPS | $**2.00** | $0.53 | $0.06 | $(0.02) | $**2.57** |

---

*Adjusted diluted earnings per share is a performance measure that excludes the impact of non-recurring transactions that we do not consider to be indicative of our ongoing operating performance. Adjusted diluted earnings per share is calculated by taking diluted earnings per share and excluding amortization of intangible assets, acquisition, integration, restructuring, and impairment costs, and any other material non-recurring costs. Acquisition, integration, restructuring and impairment costs represent costs incurred related to acquisitions, reorganizations, facilities optimization efforts, and impairments of long-lived assets, along with associated depreciation. Recovery of acquisition, integration, restructuring and impairment costs represents costs recovered through our indirect rates in accordance with Cost Accounting Standards. Adjusted diluted earnings per share also excludes amortization of intangible assets because we do not have a history of significant acquisition activity, we do not acquire businesses on a predictable cycle, and the amount of an acquisition's purchase price allocated to intangible assets and the related amortization term are unique to each acquisition. We believe that adjusted diluted earnings per share provides management and investors with useful information in assessing trends in our ongoing operating performance and may provide greater visibility in understanding the long-term financial performance of the Company.*

<sup>(1)</sup> *Non-GAAP measure, see above for definition.* 

------

**Schedule 6 (continued):**

**SCIENCE APPLICATIONS INTERNATIONAL CORPORATION**

**NON-GAAP FINANCIAL MEASURES**

**(Unaudited)**

**<u>Adjusted Diluted Earnings Per Share</u>**

---

| | | | | | | | |
|:---|:---|:---|:---|:---|:---|:---|:---|
| | **Year Ended January 30, 2026** | **Year Ended January 30, 2026** | **Year Ended January 30, 2026** | **Year Ended January 30, 2026** | **Year Ended January 30, 2026** | **Year Ended January 30, 2026** | **Year Ended January 30, 2026** |
| | **As Reported** | Amortization of intangible assets | Acquisition, integration, restructuring and impairment costs | Recovery of acquisition, integration, restructuring and impairment costs | Executive transition costs, net of recoveries | Costs related to the settlement of federal tax audits | **Non-GAAP results**<sup>(1)</sup> |
| | (in millions, except per share amounts) | (in millions, except per share amounts) | (in millions, except per share amounts) | (in millions, except per share amounts) | (in millions, except per share amounts) | (in millions, except per share amounts) | (in millions, except per share amounts) |
| Income before income taxes | $**387** | $119 | $16 | $(6) | $16 | $7 | $**539** |
| Income tax expense | **(29)** | (10) | (1) | 1 |  |  | **(39)** |
| Net income | $**358** | $109 | $15 | $(5) | $16 | $7 | $**500** |
| Diluted EPS | $**7.70** | $2.34 | $0.33 | $(0.11) | $0.34 | $0.15 | $**10.75** |

---

---

| | | | | | |
|:---|:---|:---|:---|:---|:---|
| | **Year Ended January 31, 2025** | **Year Ended January 31, 2025** | **Year Ended January 31, 2025** | **Year Ended January 31, 2025** | **Year Ended January 31, 2025** |
| | **As Reported** | Amortization of intangible assets | Acquisition, integration, restructuring and impairment costs | Recovery of acquisition, integration, restructuring and impairment costs | **Non-GAAP results**<sup>(1)</sup> |
| | (in millions, except per share amounts) | (in millions, except per share amounts) | (in millions, except per share amounts) | (in millions, except per share amounts) | (in millions, except per share amounts) |
| Income before income taxes | $**428** | $115 | $6 | $(3) | $**546** |
| Income tax expense | **(66)** | (18) | (1) |  | **(85)** |
| Net Income | $**362** | $97 | $5 | $(3) | $**461** |
| Diluted EPS | $**7.17** | $1.92 | $0.10 | $(0.06) | $**9.13** |

---

*Adjusted diluted earnings per share is a performance measure that excludes the impact of non-recurring transactions that we do not consider to be indicative of our ongoing operating performance. Adjusted diluted earnings per share is calculated by taking diluted earnings per share and excluding amortization of intangible assets, acquisition, integration, restructuring, and impairment costs, and any other material non-recurring costs. Acquisition, integration, restructuring and impairment costs represent costs incurred related to acquisitions, reorganizations, facilities optimization efforts, and impairments of long-lived assets, along with associated depreciation. Recovery of acquisition, integration, restructuring and impairment costs represents costs recovered through our indirect rates in accordance with Cost Accounting Standards. Adjusted diluted earnings per share also excludes amortization of intangible assets because we do not have a history of significant acquisition activity, we do not acquire businesses on a predictable cycle, and the amount of an acquisition's purchase price allocated to intangible assets and the related amortization term are unique to each acquisition. Executive transition costs, net of recoveries, represent costs associated with the departure of our CEO and other executives in the third quarter of the fiscal year 2026, net of the portion recovered through our indirect rates in accordance with Cost Accounting Standards. Costs related to the settlement of federal tax audits represent costs related to the IRS audit settlement for fiscal years 2016 through 2019. We believe that adjusted diluted earnings per share provides management and investors with useful information in assessing trends in our ongoing operating performance and may provide greater visibility in understanding the long-term financial performance of the Company.*

<sup>(1)</sup> *Non-GAAP measure, see above for definition.* 

------

**Schedule 6 (continued):**

**SCIENCE APPLICATIONS INTERNATIONAL CORPORATION**

**NON-GAAP FINANCIAL MEASURES**

**(Unaudited)**

**<u>Free Cash Flow</u>**

---

| | | | | |
|:---|:---|:---|:---|:---|
| | **Three Months Ended** | **Three Months Ended** | **Year Ended** | **Year Ended** |
| | **January 30, 2026** | January 31, 2025 | **January 30, 2026** | January 31, 2025 |
| | (in millions) | (in millions) | (in millions) | (in millions) |
| **Net cash provided by operating activities** | $**258** | $115 | $**609** | $494 |
| Expenditures for property, plant, and equipment | **(8)** | (15) | **(32)** | (36) |
| Cash used from (provided by) MARPA Facility | **86** | 136 | **—** | 41 |
| **Free cash flow**<sup>(1)</sup> | $**336** | $236 | $**577** | $499 |

---

---

| | |
|:---|:---|
| | **FY27 Guidance**<br>(in millions) |
| **Net cash provided by operating activities** | **>$635M** |
| Expenditures for property, plant, and equipment | Approximately $35M |
| **Free cash flow**<sup>(1)</sup> | **>$600M** |

---

*Free cash flow is calculated by taking cash flows provided by operating activities less expenditures for property, plant, and equipment and less cash flows from our Master Accounts Receivable Purchasing Agreement (MARPA Facility) for the sale of certain designated eligible U.S. government receivables. Under the MARPA Facility, the Company can sell eligible receivables up to a maximum amount of $300 million. We believe that free cash flow provides management and investors with useful information in assessing trends in our cash flows and in comparing them to other peer companies, many of whom present similar non-GAAP liquidity measures. These measures should not be considered as a measure of residual cash flow available for discretionary purposes.*

<sup>(1)</sup> *Non-GAAP measure, see above for definition.* 

<br>